№ lp_1_2_12082
File format: docx Character count: 2724 File size: 1536 KB
The document outlines the proposal to expand the IHC WorkMed Building in Ogden and includes details for the Planning Commission’s review of the conditional use permit request.
Year: 2022
Region / City: Ogden
Subject: Urban Planning, Conditional Use Permit, Building Expansion
Document Type: Planning Commission Agenda
Authority: Ogden City Planning Commission
Contact Person: Haylie Hale
Target Audience: Local planning officials, developers
Action Period: Not specified
Approval Date: February 2, 2022
Date of Amendments: None
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.

The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Supplementary Table 3. Analysis of IHC markers
Year: Not specified
Region / City: Not specified
Topic: Immunohistochemistry markers analysis
Document type: Research table
Organization / Institution: Not specified
Author: Not specified
Target audience: Researchers in histopathology, immunology, or related fields
Period of validity: Not specified
Approval date: Not specified
Date of changes: Not specified
Amendment to MBS item 72814 for programmed death ligand 1 (PD-L1) immunohistochemistry (IHC) testing to include testing for advanced triple negative breast cancer (TNBC) patients
Year: 2023
Region / City: Australia
Subject: Health / Oncology
Document Type: Official Announcement
Organization: Department of Health and Aged Care
Author: Medical Services Advisory Committee (MSAC), Pharmaceutical Benefits Advisory Committee (PBAC)
Target Audience: Healthcare providers, specialists
Effective Date: 1 September 2023
Approval Date: 10 August 2023
Changes Date: 1 September 2023
Clinical Category: Pathology Services
Procedure Type: Type C
Private Health Insurance Classification: Support List (pathology)
MBS Item: 72814
PBS Listing: pembrolizumab (Keytruda®)
Eligibility Criteria: Advanced TNBC, PD-L1 Combined Positive Score (CPS) ≥10
Consulted Stakeholders: Clinical experts, providers, consumer health representatives
Review and Monitoring: Compliance audits
More Information: www.mbsonline.gov.au
Description: Official update on the inclusion of PD-L1 immunohistochemistry testing for advanced triple negative breast cancer (TNBC) patients under the Medicare Benefits Schedule (MBS) effective 1 September 2023, aligned with PBS listing for pembrolizumab.
Clinical Sample Patient Information of RT-qPCR, Immunohistochemistry Staining (IHC), and Western Blot (WB)
Year: NA
Region / City: NA
Topic: Clinical sample analysis
Document Type: Research Data
Organization / Institution: NA
Author: NA
Target Audience: NA
Period of Validity: NA
Approval Date: NA
Date of Changes: NA
Contextual description: Data presentation of patient samples analyzed by RT-qPCR, immunohistochemistry, and Western blot methods.
Topics: WorkMed 1355 IHC